2.26
Diabetic Nephropathy
Definition
Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.
Prevalence
It is the most common cause of c…
Diabetic nephropathy is a chronic microvascular complication of diabetes driven by prolonged hyperglycemia and associated metabolic and hemodynamic changes within the kidney.
In early stages, hyperglycemia increases tubular reabsorption, triggering renal feedback–mediated afferent arteriolar vasodilation and glomerular hyperfiltration.
The resulting intraglomerular hypertension mechanically injures the filtration barrier.
In parallel, nonenzymatic glycation of basement membrane and mesangial proteins thickens and stiffens the glomerular basement membrane while reducing its negative charge selectivity.
This process reduces the negative charge of the glomerular basement membrane, decreasing repulsion of negatively charged proteins like albumin.
Microalbuminuria initially develops and progresses to macroalbuminuria as injury advances.
Persistent damage expands the mesangial matrix and produces diffuse and nodular glomerulosclerosis, steadily reducing the glomerular filtration rate.
This promotes sodium retention and RAAS activation, leading to hypertension and progressive nephron loss.
View the full transcript and gain access to JoVE Core videos
Q1: What causes diabetic nephropathy to develop in the kidneys?
Diabetic nephropathy develops from prolonged hyperglycemia, which triggers hemodynamic and metabolic changes in the kidney. Early on, hyperglycemia increases tubular reabsorption and causes afferent arteriolar vasodilation, leading to glomerular hyperfiltration. This raises intraglomerular capillary pressure, placing mechanical stress on the filtration barrier and initiating kidney damage.
Q2: How does nonenzymatic glycation damage the glomerular basement membrane?
Nonenzymatic glycation of basement membrane and mesangial proteins thickens and stiffens the glomerular basement membrane while reducing its negative charge selectivity. This loss of negative charge decreases repulsion of negatively charged proteins like albumin, increasing membrane permeability and allowing proteins to leak into the urine.
Q3: What is the relationship between microalbuminuria and disease progression?
Microalbuminuria, defined as urinary albumin excretion of 30–300 mg/day, is the first clinical indicator of diabetic nephropathy. As kidney injury advances, microalbuminuria progresses to macroalbuminuria (≥300 mg/day), reflecting more extensive glomerular damage and structural disruption of the filtration barrier and basement membrane.
Q4: How does persistent glomerular injury lead to kidney function decline?
Persistent damage expands the mesangial matrix and produces diffuse and nodular glomerulosclerosis, steadily reducing the glomerular filtration rate. This promotes sodium retention and renin-angiotensin-aldosterone system activation, leading to hypertension and progressive nephron loss that can culminate in end-stage renal disease.
Q5: Why is diabetic nephropathy considered a microvascular complication of diabetes?
Diabetic nephropathy is a chronic microvascular complication because it damages small blood vessels within the kidney glomeruli. The disease is driven by prolonged hyperglycemia and associated metabolic changes that injure the delicate filtration structures, distinguishing it from macrovascular complications affecting larger vessels.
Q6: What role does the renin-angiotensin system play in diabetic nephropathy progression?
As glomerular filtration rate declines, sodium retention activates the renin-angiotensin-aldosterone system, which raises blood pressure and accelerates nephron loss. This creates a cycle of progressive kidney damage. Renin-angiotensin system blockade is a key therapeutic strategy to slow disease progression and preserve kidney function.
Q7: How is diabetic nephropathy detected and monitored clinically?
Monitoring albuminuria and estimated glomerular filtration rate is essential for early detection of diabetic nephropathy. Optimal glycemic and blood pressure control, along with renin-angiotensin system blockade, can slow disease progression. Early intervention based on these markers helps prevent advancement to complications of diabetes mellitus.